Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 287

1.

Engineering T-Cell Specificity Genetically to Generate Anti-melanoma Reactivity.

Weizman E, Cohen CJ.

Methods Mol Biol. 2016 Jan 20. [Epub ahead of print]

PMID:
26786881
2.

Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.

van Lunzen J, Antinori A, Cohen CJ, Arribas JR, Wohl DA, Rieger A, Rachlis A, Bloch M, Segal-Maurer S, Garner W, Porter D, Bosse M, Piontkowsky D, Chuck SK, De-Oertel S.

AIDS. 2016 Jan;30(2):251-9. doi: 10.1097/QAD.0000000000000911.

PMID:
26684822
3.

Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist.

Ahuja S, Mukund S, Deng L, Khakh K, Chang E, Ho H, Shriver S, Young C, Lin S, Johnson JP Jr, Wu P, Li J, Coons M, Tam C, Brillantes B, Sampang H, Mortara K, Bowman KK, Clark KR, Estevez A, Xie Z, Verschoof H, Grimwood M, Dehnhardt C, Andrez JC, Focken T, Sutherlin DP, Safina BS, Starovasnik MA, Ortwine DF, Franke Y, Cohen CJ, Hackos DH, Koth CM, Payandeh J.

Science. 2015 Dec 18;350(6267):aac5464. doi: 10.1126/science.aac5464.

PMID:
26680203
4.

In-vitro Optimization of Nanoparticle-Cell Labeling Protocols for In-vivo Cell Tracking Applications.

Betzer O, Meir R, Dreifuss T, Shamalov K, Motiei M, Shwartz A, Baranes K, Cohen CJ, Shraga-Heled N, Ofir R, Yadid G, Popovtzer R.

Sci Rep. 2015 Oct 28;5:15400. doi: 10.1038/srep15400.

5.

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.

Wilkins EL, Cohen CJ, Trottier B, Esser S, Smith DE, Haas B, Brinson C, Garner W, Chuck S, Thorpe D, De-Oertel S.

AIDS Care. 2016 Mar;28(3):401-8. doi: 10.1080/09540121.2015.1096890. Epub 2015 Oct 21.

PMID:
26489045
6.

The genetic association of RUNX3 with ankylosing spondylitis can be explained by allele-specific effects on IRF4 recruitment that alter gene expression.

Vecellio M, Roberts AR, Cohen CJ, Cortes A, Knight JC, Bowness P, Wordsworth BP.

Ann Rheum Dis. 2015 Oct 9. pii: annrheumdis-2015-207490. doi: 10.1136/annrheumdis-2015-207490. [Epub ahead of print]

7.

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.

Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

J Clin Invest. 2015 Oct 1;125(10):3981-91. doi: 10.1172/JCI82416. Epub 2015 Sep 21.

8.

Nanomedicine for Cancer Immunotherapy: Tracking Cancer-Specific T-Cells in Vivo with Gold Nanoparticles and CT Imaging.

Meir R, Shamalov K, Betzer O, Motiei M, Horovitz-Fried M, Yehuda R, Popovtzer A, Popovtzer R, Cohen CJ.

ACS Nano. 2015 Jun 23;9(6):6363-72. doi: 10.1021/acsnano.5b01939. Epub 2015 Jun 11.

PMID:
26039633
9.

An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.

Tal Y, Yaakobi S, Horovitz-Fried M, Safyon E, Rosental B, Porgador A, Cohen CJ.

Oncotarget. 2014 Nov 15;5(21):10949-58.

10.

Inhibitors of voltage-gated sodium channel Nav1.7: patent applications since 2010.

Sun S, Cohen CJ, Dehnhardt CM.

Pharm Pat Anal. 2014 Sep;3(5):509-21. doi: 10.4155/ppa.14.39. Review. Erratum in: Pharm Pat Anal. 2014;3(6):640.

PMID:
25374320
11.

The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.

Sun S, Jia Q, Zenova AY, Chafeev M, Zhang Z, Lin S, Kwan R, Grimwood ME, Chowdhury S, Young C, Cohen CJ, Oballa RM.

Bioorg Med Chem Lett. 2014 Sep 15;24(18):4397-401. doi: 10.1016/j.bmcl.2014.08.017. Epub 2014 Aug 14.

PMID:
25176194
12.

High-risk case identification for use in comprehensive complex care management.

Cohen CJ, Flaks-Manov N, Low M, Balicer RD, Shadmi E.

Popul Health Manag. 2015 Feb;18(1):15-22. doi: 10.1089/pop.2014.0011. Epub 2014 Jul 30.

PMID:
25075954
13.

Social values as an independent factor affecting end of life medical decision making.

Cohen CJ, Chen Y, Orbach H, Freier-Dror Y, Auslander G, Breuer GS.

Med Health Care Philos. 2015 Feb;18(1):71-80. doi: 10.1007/s11019-014-9581-x.

PMID:
24965073
14.

Reduction in myocardial infarction incidence: focus on socioeconomic disparities.

Reges O, Leibowitz M, Hoshen M, Rabi Y, Gluzman I, Cohen CJ, Balicer RD.

Int J Cardiol. 2014 Jul 1;174(3):773-4. doi: 10.1016/j.ijcard.2014.04.073. Epub 2014 Apr 15. No abstract available.

PMID:
24794958
15.
16.

Letter to the editor.

Goldberg YP, Cohen CJ, Namdari R, Price N, Cadieux JA, Young C, Sherrington R, Pimstone SN.

Pain. 2014 Apr;155(4):837-8. doi: 10.1016/j.pain.2014.01.003. Epub 2014 Jan 13. No abstract available.

PMID:
24434731
17.

Pneumococcal vaccine targeting strategy for older adults: customized risk profiling.

Balicer RD, Cohen CJ, Leibowitz M, Feldman BS, Brufman I, Roberts C, Hoshen M.

Vaccine. 2014 Feb 12;32(8):990-5. doi: 10.1016/j.vaccine.2013.12.020. Epub 2013 Dec 31.

PMID:
24384054
18.

Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.

Ankri C, Shamalov K, Horovitz-Fried M, Mauer S, Cohen CJ.

J Immunol. 2013 Oct 15;191(8):4121-9. doi: 10.4049/jimmunol.1203085. Epub 2013 Sep 11.

19.
20.

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, Bloch M, Garner W, Guyer B, Williams S, Chuck S, Vanveggel S, Deckx H, Stevens M.

HIV Clin Trials. 2013 May-Jun;14(3):81-91. doi: 10.1310/hct1403-81.

PMID:
23835510
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk